Your search matched 16 results
Climate change is named a top 10 health threat and we’ve broken down the conundrum for pharma companies regarding activating on the issue.
SCOTUS is weighing its options on a number of healthcare cases; using social activism to tip the scales for your brand reputation; and crowdfunding for what?
The Week That Was: ... | Blog
Our favorite #healthpolicyvalentines, new FDA guidance regarding complex generics and what you need to know now regarding data security from pharma and patient perspectives.
Policymakers continue their focus on drug pricing and may also have eyes for changes to the Orphan Drug Act.
You think you’re busy?
Winter is coming… in May.
What do vacationers on a cruise ship in St.
This week's edition of The Week That Was details how health and medical groups are taking action to address the “greatest public health challenge of the 21st century” and what you need to know from a busy week in healthcare policy.
As drug pricing continues to be under the microscope, it’s a tough environment for drug makers.
Missed BIO 2019?
“Timing is everything - particularly when lives are at stake.”
80% of voters support importing drugs from Canada and politicians on both sides of the aisle agree.
It’s seems like it’s being marketed as a treatment for everything from pain to anxiety, but is it legal?
This week’s edition of The Week That Was details how the Business Roundtable’s “Statement on the Purpose of a Corporation” shifts businesses’ focus from solely shareholders to all stakeholders.
A recent survey found 70% of investors decreased interest in buying IPOs compared to last spring.